Global Technologies, Ltd. Announces Its Financial Results for the Quarter Ended September 30, 2024 with Major Financial Highlights and Accomplishments $GTLL See Full Release Here: bit.ly/4epOnM2

Our revenue soared by $669,431 for the quarter ended September 30, 2024, marking an impressive 100% increase. We’re excited about our continued growth and success! $GTLL #revenuegrowth #innovation

Thrilled to announce a $4,842,205 rise in Shareholder Equity between September 2023 and September 2024. This milestone reflects our dedication to sustainable financial growth. $GTLL #financialgrowth

Global Technologies, Ltd Announces H. “Wyatt” Flippen as Its New Chief Executive Officer $GTLL See Full Release: yhoo.it/3B64sbZ

$GTLL Global Technologies, Ltd. New CEO has spent a lot of time and effort to reposition for success. 3 straight quarters of profits and reduced debt. He has cleaned up the meds of the past and will see .01+ soon and more. Best investment in OTC right now.

Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector $GTLL See Full Release: rebrand.ly/qg7r1zl

Wyatt Flippen here — sending you my first post on X. This is part of GTLL’s new communication initiative: full transparency, direct updates, and real engagement with our shareholders and supporters. Here’s the latest on $GTLL 👇 📷

Since Dec 2024, we’ve restructured operations, strengthened financial controls, and focused growth on our health-tech subsidiaries — Primecare Supply & GloWell Advisors. Our FY25 audit is well underway.👇

In Aug 2025, the SEC issued a comment letter that required us to terminate our prior auditor mid-stream. We’ve engaged a new U.S.-based PCAOB auditor conducting a 2-year review (FY24 & FY25). We’ve reached out to the SEC for guidance — but they’re currently closed.

Part 4: Catch up on our latest filings and updates: 8-K tinyurl.com/GTLL9820258K 8-K tinyurl.com/GTLL9420258K 8-K tinyurl.com/GTLL9320258K The FY25 10-K is coming soon — stay tuned here. #GTLL #AuditUpdate

Part 5: Catch up on our latest filings and updates: 📷 10-Q (FY25 Q3) tinyurl.com/GTLL10Q3312025 📷 Press: Primecare & GloWell expansion tinyurl.com/GTLL82220258k #GTLL #Primecare #GloWellAdvisors #HealthTech #AuditUpdate

We listened, adapted, and built a stable model for the fast-growing wellness market. Primecare now operates as a software + procurement agency with higher margins and control via our Sinq Ops system. Sales are climbing steadily. $GTLL #GTLL #Primecare #HealthTech #Growth

The global wellness economy reached $6.3T and is expected to top $9T by 2028. Health, tech, and transparency are driving the new era of patient empowerment. $GTLL #WellnessEconomy #HealthTech Source: bit.ly/4ouXroV

Good Afternoon. As I reported in 10/15, Our FY24 and FY25 audits remains in process. I know it’s frustrating but this is the last big hurdle between our past and our future. Our team, new auditors, old auditors, CPA, 10Fold execs, and past leaders are all working daily to get

“Growth requires structure. At GTLL, scalability begins with compliance and ends with innovation.” – H. Wyatt Flippen, CEO  $GTLL #Leadership #CorporateGovernance

Our commitment 11 months ago was to do the hard work to rebuild the company for sustainable success. It took months to gain complete control of all the arms and legs. This audit process is a painful but necessary step. We’re almost there. We are in balance sheet testing and

$GTLL Quick update as we close the week: We don’t expect anything unusual with the audit. With a new PCAOB auditor, reviewing two years (FY24 & FY25) is standard, and we chose to take that full look-back to strengthen accuracy and transparency. Numbers are being finalized as we

AI use in healthcare jumped from 25% to 70% since 2020. Data, precision, and automation are now essential. $GTLL #AIinHealthcare #HealthTech Source: bit.ly/3LhdrMr

$GTLL When I first arrived, our focus was survival, undo bad deals and pick one business to build on. We chose the ultra high-growth Wellness market. With limited options, we started brokering pharma deals through 10Fold high volume, low-margin cashflow work that generated our